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Abstract
Background: Hepatitis C virus (HCV) infection is a major public health problem with more than 170 million cases of 
chronic infections worldwide. There is no protective vaccine currently available for HCV, therefore the development of 
novel strategy to prevent chronic infection is important. We reported earlier that a recombinant human antibody clone 
blocks viral NS3 helicase activity and inhibits replication of HCV 1b virus. This study was performed further to explore 
the mechanism of action of this recombinant antibody and to determine whether or not this antibody inhibits 
replication and infectivity of a highly efficient JFH1 HCV 2a virus clone.
Results: The antiviral effect of intracellular expressed antibody against the HCV 2a virus strain was examined using a 
full-length green fluorescence protein (GFP) labeled infectious cell culture system. For this purpose, a Huh-7.5 cell line 
stably expressing the NS3 helicase gene specific IgG1 antibody was prepared. Replication of full-length HCV-GFP 
chimera RNA and negative-strand RNA was strongly inhibited in Huh-7.5 cells stably expressing NS3 antibody but not 
in the cells expressing an unrelated control antibody. Huh-7.5 cells stably expressing NS3 helicase antibody effectively 
suppressed infectious virus production after natural infection and the level of HCV in the cell free supernatant 
remained undetectable after first passage. In contrast, Huh-7.5 cells stably expressing an control antibody against 
influenza virus had no effect on virus production and high-levels of infectious HCV were detected in culture 
supernatants over four rounds of infectivity assay. A recombinant adenovirus based expression system was used to 
demonstrate that Huh-7.5 replicon cell line expressing the intracellular antibody strongly inhibited the replication of 
HCV-GFP RNA.
Conclusion: Recombinant human anti-HCV NS3 antibody clone inhibits replication of HCV 2a virus and infectious virus 
production. Intracellular expression of this recombinant antibody offers a potential antiviral strategy to inhibit 
intracellular HCV replication and production.
Background
Hepatitis C virus (HCV) infection is a blood borne infec-
tious disease that affects the liver. Only a small fraction of
infected individuals clear the HCV infection naturally. In
the majority of cases, the virus infection overcomes the
host innate and adaptive immune responses leading to a
stage of chronic infection. It has been well recognized
that chronic HCV infection often leads to a progressive
liver disease including cirrhosis and liver cancer. There
are 170 million people representing 3% of the world's
population that are chronically infected with HCV . The
incidence of new infection continues to rise each year at
the rate of 3-4 million [1]. Therefore, HCV infection is
considered a major health-care problem worldwide. At
present there is no prophylactic antibody or therapeutic
vaccine available. The only treatment option for chronic
HCV infection is the combination of interferon and riba-
virin [2]. This therapy is not effective in clearing all
chronic HCV infections. Interferon therapy is also very
costly and has substantial side effects. There is a need for
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the development of improved antiviral therapies for the
treatment of chronic HCV infection.
Hepatitis C virus is a positive-stranded RNA virus con-
taining a single RNA genome of 9600 nucleotides in
length [3]. The virus genome contains a short 341 nucle-
otides untranslated region (5'UTR) followed by a long
open reading frame (ORF), ending with a short 3'
untranslated region. The HCV genome can persist in the
infected liver cells due to continuous replication of posi-
tive-stranded RNA genome. The 5' UTR of HCV RNA is
crucial for the initiation of protein synthesis. This com-
ponent of viral genome recognizes the host ribosome and
translates HCV proteins by an IRES dependent mecha-
nism. A single large polyprotein of 3010 amino acids is
translated from the long open reading frame (ORF)
encoded within the viral RNA genome. This large protein
is then cleaved into 10 different individual proteins by the
combined action of the cellular and viral proteases. The
viral core, E1, E2, and P-7 proteins are called the struc-
tural proteins required for the production of infectious
virus particles, their secretion and infection. The remain-
ing non-structural proteins (NS2, NS3, NS4A, NS4B,
NS5A, NS5B) are essential for replication of HCV posi-
tive and negative strand RNA. Among these non-struc-
tural proteins, NS3 is the viral protease and NS5B is the
viral polymerase. These two proteins have been the tar-
gets of novel drug discovery [4,5]. There are now large
numbers of HCV inhibitors in the clinical developments
targeting these two proteins and these new drugs in com-
bination may improve the treatment of chronic HCV
infection [6].
Several novel antiviral strategies also have been devel-
oped using HCV cell culture models including antisense
oligonucleotides [7-10], siRNAs [11-15], and recombi-
nant antibodies [16-34]. Hepatitis C virus shows chronic
persistent infection in the liver, even in the presence of
circulating antibodies to both the structural and non-
structural proteins. The vast majority of these circulating
antibodies do not inhibit intracellular virus production
and replication. Antibody-mediated neutralization of
intracellular and extracellular virus replication and infec-
tion is a novel approach to treat chronic viral infection.
The rationale of the current study is to develop an intrac-
ellular treatment approach for chronic HCV infection by
using recombinant antibody technology. During the past
few years, significant progress has been made in the
design, selection, and production of engineered antibod-
ies [35,36]. Antibodies can be reduced in size, rebuilt into
multivalent molecules and conjugated with drugs, toxins,
or radioisotopes for the treatment of cancer, autoimmune
disorders, graft rejection, and infectious diseases.
We have developed a human monoclonal antibody
clone derived from a chronically infected patient that
effectively inhibits NS3 helicase activity [29-31]. We
showed that intracellular expression of this recombinant
antibody clone from a plasmid vector inhibits helicase
activity and replication of HCV 1b virus [30]. Here we
further explore the mechanism of action of this recombi-
nant antibody and demonstrate that it also inhibits repli-
cation of another HCV strain. A Huh-7.5 cell expressing
NS3 antibody was developed. We show that replication
and infectivity of HCV 2a virus was effectively inhibited
in Huh-7.5 cells expressing NS3 antibody. The replication
and infectivity of HCV 2a virus was not altered in Huh-
7.5 cells expressing control antibody against influenza
virus.
Materials and methods
Cell lines and plasmid clones
Huh-7.5 cells were obtained from the laboratory of Dr.
Charles M Rice (Center for the Study of Hepatitis C, The
Rockefeller University, New York) and cells were cultured
in Dulbecco's Modified Eagle Medium (DMEM; Invitro-
gen, San Diego, CA) with high glucose supplemented
with non-essential amino acids, sodium pyruvate and 5%
fetal bovine serum. A full-length JFH-1 clone and repli-
con plasmid (pSGR-JFH1) were obtained from Dr. Takaji
Wakita [37] (National Institute of Infectious Diseases,
Tokyo, Japan). Full-length and sub-genomic JFH1-GFP
was constructed by inserting the coding sequence of
green fluorescence protein in the NS5A gene described
before [38].
Development of stable Huh-7.5 cell lines expressing IgG1 
antibody
The construction of plasmid vector pFab-CMV-NS3
(L+H) containing light chain, heavy chain, CH2-CH3,
and part of the hinge region for a germline immunoglob-
ulin 1 was described previously [30]. This vector allows
conversion of recombinant Fab antibody into a complete
IgG1 antibody in the transfected cells. Huh-7.5 cells were
electroporated with 10 μg of pFab-CMV (H+L) plasmid
DNA. After 24 hours, cells were selected with a growth
medium containing G-418 (500 μg/ml). A control stable
Huh-7.5 cell line was prepared that expressed IgG1 anti-
body targeted to influenza A viruses (clone Fab-9) [39].
These two Huh7.5 lines stably expressing intracellular
antibody were cultured in a growth medium containing
G-418 (500 μg/ml). Intracellular expression of IgG1 anti-
body in these two stable cell lines was confirmed by
immunofluorescence microscopy. Briefly, cells cultured
in chamber slides were washed with phosphate-buffered
saline (PBS) pH 7.4 twice, air-dried and fixed with chilled
acetone for 5 min. The cells were permeabilized by the
treatment with 0.05% saponin for 10 min at room tem-
perature. Blocking was performed with 5% fetal bovine
serum (FBS) diluted in a minimum essential medium for
5 min at room temperature. The slides were washed withChandra et al. Virology Journal 2010, 7:118
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PBS thrice for 5 min each. The cells were incubated with
goat anti-human phycoerythrin conjugated antibody
(anti-human-IgG-γ chain specific-R-Phycoerythrin,
Sigma-Aldrich, Saint Louis, MO) at 1:50 dilution (in
DMEM+5% FBS) for 1 hour. When staining was com-
pleted, the slides were washed three times with PBS and
mounted with hoechst dye (H33342, Calbiochem, Darm-
stadt, Germany) at a concentration of 10 μg/ml prepared
in water containing 50% glycerol. Finally, the slides were
examined under a fluorescence microscope at 563 nm for
the red fluorescence and 340 nm for blue fluorescence.
For each area, two sets of pictures were generated. Super-
imposing blue with red fluorescence using the Abode
Photoshop computer software (V 7.0) generated the final
image.
Replication Assay
The effect of an intracellular antibody expression in Huh-
7.5 cells on the replication of full-length JFH1-GFP RNA
genome was examined by using a transfection based rep-
lication assay. Full-length in vitro HCV-GFP RNA tran-
scripts were prepared from XbaI  digested linearized
pJFH1-GFP plasmid by using a commercially available
MEGA script kit (Ambion Inc, Austin, TX). The HCV
RNA pellet was re-suspended in nuclease free water and
20 μg aliquots of this RNA was stored at -80°C. Approxi-
mately, 2 × 107 cells were re-suspended in 400 μl of serum
free DMEM, mixed with 20 μg of in vitro transcribed
RNA and was electroporated using a Gene Pulser Xcell
apparatus (Bio-Rad Laboratories Inc. Hercules, CA) with
the condition 260 V, 960 μF. Following this step, cells
were cultured in DMEM with 10% fetal bovine serum.
The expression of GFP due to HCV replication was mon-
itored under a fluorescence microscope (Olympus 1 × 70)
with every 24 hours interval and the images were cap-
tured using an Olympus DP-71 digital camera. Positive-
and negative-strand HCV-RNA in the transfected cells
was detected by ribonuclease protection assay (RPA).
Briefly, total RNA was isolated from the HCV transfected
cells every 24 hours by the GITC method and subjected
to RPA using a probe targeted to the 5'UTR of HCV. The
same amounts of the RNA extracts were subjected to
RPA for GAPDH mRNA. To detect HCV RNA, we pre-
pared a plasmid construct called pCR-II-NT-218, which
have the sequence of 79-297 nucleotides of 5'UTR
sequence of the JFH-1 clone. This plasmid was linearized
with HindIII enzyme and positive strand RNA probe was
prepared using T7 RNA polymerase to detect the HCV
negative strand RNA. Likewise, this plasmid was linear-
ized with the Xba I restriction enzyme and Sp6 RNA
polymerase was used to prepare a negative-strand RNA
probe for the detection of a positive-strand HCV RNA.
We used a linearized plasmid pTRI-GAPDH-human anti-
sense control template was used to prepare probe to
detect GAPDH mRNA using Sp6 RNA polymerase
(Ambion Inc., Austin, TX).
Infectivity Assay
The effect of intracellular antibody expression on produc-
tion of infectious HCV was examined by multicycle infec-
tivity assay [38]. Huh-7.5 cells were transfected with 20 μg
of in vitro transcribed full-length JFH1-GFP RNA by
electroporation method. After 96 hours, cells were col-
lected by scraping and lysed by four rounds of freeze-
thaw cycles. The cell lysates were clarified by centrifuga-
tion at 3400 rpm for five minutes. The clear supernatant
was collected and titer of HCV in the supernatant was
determined by real-time RT-PCR using a primer set tar-
geted to the 5'UTR. Tissue culture infective dose
(TCID50 and MOI) of the virus stock was determined
using 10-fold serial dilution of the virus containing super-
natant using 2-well Lab-Tek chamber slides (Nalge-Nunc
International, Rochester, New York). Huh-7.5 cells stably
expressing intracellular antibody were seeded at a density
of 1 × 106 cells/100 mm plate. The next day the culture
medium was removed and cells were infected with 3 ml
of culture supernatant containing infectious virus (5 ×
105 virus particles/ml, MOI 1.5). After overnight incuba-
tion, the cells washed three times using 10 ml of PBS and
incubated with 10 ml of complete growth medium. Cell
free culture supernatants were collected after 96 hours,
clarified by centrifugation. Three ml of culture superna-
tants was used to infect new batch of antibody expressing
Huh-7.5 cells. The infectivity assay was performed up to
four cycles each using the identical procedure. At the end
of infectivity assay, RNA was isolated from 1 ml of culture
supernatants and HCV RNA titer was measured by real-
time RT-PCR.
Real time reverse transcription polymerase chain reaction 
(RT-PCR)
Real time RT-PCR was performed to quantify HCV RNA
levels in the infected cell culture using a published proto-
col [40]. The 243 bp HCV DNA was amplified from the
RNA extract by reverse transcription polymerase chain
reaction using the outer sense (OS) primer 5'-GCA-
GAAAGCGCCTAGCCATGGCGT-3' (67-90) and outer
anti-sense (OAS) primer 5'-CTCGCAAGCGCCCTAT-
CAGGCAGT-3' (287-310). First the complementary
DNA synthesis was performed from positive-strand
HCV-RNA using an outer anti-sense primer (OAS) tar-
geted to the highly conserved 5'UTR region of HCV in 20
μl volume. Briefly, 2 μg of total cellular RNA were mixed
with 1 μl OAS primer (200 ng/μl), denaturized at 65°C for
10 minutes and annealed at room temperature. Avian
myeloblastosis virus (AMV) reverse transcriptase (10 U)
(Promega, Madison, WI) was added and incubated at
42°C for 60 minutes in the presence of 50 mmol/L Tris,Chandra et al. Virology Journal 2010, 7:118
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pH 8.3, 50 mmol/L ethylenediaminetetraacetic acid
(EDTA), 500 nmol/L dNTP, 250 nmol/L spermidine, and
40 U RNasin (Promega, Madison, WI). The cDNA was
stored at -20°C until use. SYBR Green real time PCR
amplification was performed in 20 μl of volume contain-
ing 10 μl of SYBR Green ER qPCR SuperMix, 1 μl (250
ng/ul) of sense and antisense primer with 4 μl of cDNA
and 4 μl of distilled water. All samples were run in tripli-
cate. The amplification was carried out using the stan-
dard program recommended by Bio-Rad Laboratory that
includes: 50°C for 2 minutes, 95°C for 8 minutes, then
additional 50 cycles wherein each cycle consists of a
denaturation step at 95°C for 10 seconds, and annealing
and extension step at 60°C for 30 seconds. At the end of
the amplification cycles, melting temperature analysis
was performed by a slow increase in temperature (0.1°C/
s) up to 95°C. Amplification, data acquisition, and analy-
sis were performed on CFX96 Real-Time instrument
using CFX manager software (Bio-Rad, Hercules, CA).
Construction of adenovirus vector containing IgG1 
antibody
A replication defective adenovirus construct carrying the
gene for the recombinant human antibody (Ad-IgG1) was
prepared using standard PCR and cloning methods. We
used the pFab-CMV-NS3 (L+H) plasmid construct to
prepare a recombinant adenovirus vector (30). The clon-
ing process was carried out in multiple steps. First, the
heavy chain antibody expression cassette containing the
CMV promoter-antibody ORF, Fd termination sequence
and heavy chain polyadenylation sequences were PCR
amplified and assembled in pGEM-7Z(f+) vector (Pro-
mega, Madison, WI) using XhoI  and  BamHI sites. An
unique HindIII site was introduced before the XhoI and
BamHI site such that the entire antibody expression cas-
sette can be excised from the pGEM-7Z(f+) plasmid and
inserted into the adenovirus pShuttle Vector (QBIOgene,
AES1020, without CMV promoter) using a unique Hin-
dIII site. After cloning, the exact orientation of the heavy
chain antibody expression cassette was confirmed by
DNA sequence analysis. At the second step, the antibody
light chain gene was inserted into the same plasmid shut-
tle (pShuttle vector without CMV promoter) using two
PCR fragments. The first light chain CMV promoter-
leader sequence and light chain ORF was cloned into a
pShuttle plasmid using Kpn1 and XbaI  sites. Then the
remaining light chain termination sequence and polyade-
nylation sequences were introduced into the same pShut-
tle vector using XbaI sites. The orientation of the CMV
promoter of the light chain and heavy chain reading
frame in the resulting plasmid was confirmed by restric-
tion analysis. The recombinant plasmid is called pShuttle
CMV NS3 (H+L). The antiviral effect of recombinant
antibody clone was confirmed again by transfection into
a replicon cell line. The pShuttle CMV NS3 (H+L) anti-
body gene was then transferred into the adenoviral
genome (pAdEasy, QBiogene, Carlsbad, CA) by homolo-
gous recombination. The recombinant adenovirus plas-
mid was examined by restriction digestion analysis. The
recombinant adenovirus plasmid was linearized with a
PacI restriction enzyme and transfected to QBI-293 cells
(QBiogene, Carlsbad, CA). After several weeks, the
recombinant adenovirus was plaque purified and ampli-
fied on 293 cells. Large-scale purification of the recombi-
nant adenovirus was performed by CsCL gradient
centrifugation. The titer of recombinant adenovirus
(virus particles/ml) was determined by using absorbance
at optical density at 260 nm, a standard protocol supplied
in the kit. A recombinant adenovirus carrying firefly
luciferase (Ad-Luc) was used as a control to exclude the
non-specific effect of recombinant adenovirus infection
on HCV replication.
Immunocytochemistry
Huh-7.5 cells were cultured in chamber slides and after
24 hours they were infected with a different concentra-
tion of recombinant adenovirus (Ad-IgG1). The intracel-
lular expression of a recombinant antibody was examined
by an immunostaining method using goat anti-human
antibody (Sigma-Aldrich, Saint Louis, MO). Briefly, Huh-
7.5 cells cultured in chamber slides were washed with
phosphate-buffered saline (PBS) pH 7.4 twice, air-dried
and fixed with chilled acetone for five minutes. The cells
were permeabilized by the treatment with 0.05% saponin
for 10 minutes at room temperature. Blocking was per-
formed with 5% normal goat serum diluted in a minimum
essential medium for 30 minutes at room temperature.
Blocking for endogenous biotin-avidin was performed
using an avidin/biotin blocking kit (Vector Laboratories
Inc., Burlingame, CA). Blocking for endogenous peroxi-
dase was carried out with 0.9% H2O2 for 30 minutes at
room temperature. The cells were incubated with a biotin
conjugated goat anti-human IgG antibody (1:500 dilution,
Sigma-Aldrich, Saint Louis, MO). The slide was then
washed three times and incubated with an anti-mouse
biotin conjugated antibody (1:1000) for one hour at room
temperature. The slides were then washed and incubated
for 30 minutes with Elite avidin-biotin peroxidase com-
plex (Vector Laboratories Inc., Burlingame, CA). The
slides were reacted with diaminobenzidine for 10 min-
utes. Counterstaining was performed with hematoxylin
for one minute. After dehydration, the slides were
mounted with per mount and observed by light micros-
copy.
Western blotting
To make sure that the intracellular expressed antibody
molecule processed accurately, western blot analysis wasChandra et al. Virology Journal 2010, 7:118
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performed using lysates prepared from the adenovirus
infected Huh-7.5 cells. Immunoblotting was performed
with a peroxidase conjugated rabbit anti-human antibody
at a dilution of 1:500. (Sigma-Aldrich, Saint Louis, MO).
The membrane was developed using the enhanced-
chemiluminescence detection kit (ECL kit) (Amersham
Pharmacia, Piscataway, NJ) and was exposed to chemilu-
minescent-sensitive film (Kodak Rochestor, NY).
Results
Huh-7.5 cells stably expressing NS3 antibody inhibits HCV 
2a replication
The initial step of this study was the development of a
Huh-7.5 cell line with stable expression of intracellular
antibody. The recombinant human antibody gene was
introduced in to a mammalian plasmid expression vector
that expresses the heavy and light chain antibody gene
using the two identical CMV promoters (Fig. 1). This
allows production of equal amounts of heavy and light
chains of the antibody molecule in the cytoplasm. A sta-
ble Huh-7.5 cell line expressing NS3 antibody targeting
the HCV NS3 helicase was prepared. Another Huh-7.5
cell line stably expressing antibody against influenza virus
was used as a control. We show that both the Huh-7.5 cell
lines expresses IgG1 antibody in the cytoplasm by immu-
nological staining (Fig. 2). Stable intracellular antibody
expression ensured no cellular toxicity since these cells
can be propagated in culture for prolonged time. To study
the effect of the intracellular antibody on full-length
HCV RNA replication, we used a chimeric full-length
JFH1-GFP clone where the coding sequence of GFP was
introduced in the NS5A region [38]. We have shown that
this clone replicates in Huh-7.5 cells and produces posi-
tive- and negative-strand HCV RNA by ribonuclease pro-
tection assay. To determine the antiviral effect of
intracellular antibody expression on the replication of
full-length JFH-1 clone, full-length JFH1-GFP HCV-RNA
was transfected to stable Huh-7.5 cell lines expressing an
intracellular antibody. The effect of intracellular antibody
expression on replication of HCV was determined by
RPA assay at 0, 24, 48, 72 and 96 hours. The results of
RPA assay for the detection of positive- and negative-
strand RNA detection are shown in Fig. 3. The levels of
positive-strand RNA decreased over time and remained
undetectable at 96 hours only in the cells expressing NS3
antibody. In contrast, positive-strand HCV RNA was
detected at all time points in cells expressing an unrelated
control antibody or Huh-7.5 cells without antibody
expression. HCV is a positive-strand RNA virus that rep-
licates by a negative-strand RNA intermediate. The effect
of antibody expression on the replication of JFH1-GFP
RNA in Huh-7.5 cells was examined by measuring HCV
negative-strand RNA levels by RPA. HCV negative-
strand RNA remained undetected in Huh-7.5 cells
expressing NS3 antibody. In contrast, HCV negative-
strand RNA was detected in Huh-7.5 cells expressing
control antibody and Huh-7.5 cells without antibody
expression. These results suggest that HCV replication
was terminated in cells stably expressing intracellular
helicase antibody, while in control cells HCV replication
was unaltered. The antiviral effect of intracellular helicase
antibody was examined by green fluorescence protein
expression in a kinetic study. The expression of HCV-
GFP chimera protein specifically decreased in cells
expressing NS3 antibody and the protein expression
remained undetectable at 96 hours (Fig 4). The level of
viral RNA in the antibody expressing cells and control
Huh-7.5 cells after transfection was quantitated by using
real-time RT-PCR using a primer set targeted to the
highly conserved 5'UTR region. HCV RNA levels pro-
gressively decreased in Huh-7.5 cells expressing NS3
antibody (Fig. 5). There are significant differences in the
levels of HCV RNA between the NS3 antibody expressing
cells and two control cell lines. Taken together these
results indicate that full-length JFH1-GFP RNA replica-
tion was selectively inhibited in Huh-7.5 cells expressing
intracellular NS3 antibody.
Huh-7.5 cells stably expressing NS3 antibody inhibits 
production of intracellular and extracellular virus
The effect of intracellular NS3 antibody on the produc-
tion of infectious virus particles was examined by per-
Figure 1 The schematic diagram of the recombinant antibody 
construct. The recombinant Fab antibody clone was expressed in 
mammalian cells using the expression vector (pFab-CMV-NS3 (H+L) 
that has two identical CMV promoters. This vector was used to gener-
ate stable Huh-7.5 cells expressing intracellular IgG1 antibody.
Figure 2 Immunofluorescence staining showing stable intracyto-
plasmic expression of NS3 helicase specific antibody and control 
antibody in Huh-7.5 cells. Stable Huh-7.5 cells were seeded in 2-well 
chamber slides and after 48 hours cells were stained with phycoeryth-
rin conjugated anti-human IgG1 antibody at a dilution of 1:50. After 
this step, cells were counterstained with hoechst dye. A: Negative 
staining of control Huh 7.5 cells. B: Huh 7.5 cells stably expressing a 
control antibody. C: Huh 7.5 cells stably expressing NS3 antibody.Chandra et al. Virology Journal 2010, 7:118
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forming multicycle infectivity assay. We previously
established infectivity assay for HCV using the JFH1-GFP
clone. The infectivity of HCV can be directly determined
by examining the expression of GFP under a fluorescence
microscope. Huh-7.5 cells expressing NS3 antibody and
Huh-7.5 cells expressing control antibody were infected
with infectious HCV and replication of HCV-GFP chi-
mera after natural infection was examined in a kinetic
study. We found that the replication of HCV-GFP chi-
mera virus was inhibited in the Huh-7.5 cells expressing
NS3 antibody since we did not see any GFP expression
(Fig. 6). In contrast, HCV-GFP expression in the infected
cells was detected in both the control Huh-7.5 cells. The
infectivity assay was serially repeated an additional three
cycles using 3 ml of culture supernatants (MOI 1.5). The
production of infectious HCV in Huh-7.5 cells with or
without antibody expression was measured by real-time
RT-PCR. The results of these experiments (Fig. 7) indi-
cate that there is a significant drop in the HCV RNA lev-
els after first passage in Huh-7.5 cells expressing NS3
antibody. The levels of HCV RNA in the supernatants did
not change in Huh-7.5 cells and Huh-7.5 cells expressing
control antibody. These results clearly indicate that the
NS3 antibody prevents intracellular HCV RNA replica-
tion leading to reduced virus particle formation and
secretion.
Figure 3 HCV positive- and negative-strand RNA detection by RPA showing the complete inhibition of HCV replication in stable Huh 7.5 
cells expressing NS3 antibody (middle panel). Huh-7.5 cells were transfected with in vitro transcribed full-length HCV-GFP RNA. Cells were harvest-
ed after 0, 24, 48, 72 and 96 hours of post transfection. Total RNA was isolated and subjected to positive- and negative-strand HCV RNA detection and 
GAPDH mRNA by RPA. Upper panel: shows HCV positive- and negative-strand HCV RNA levels in Huh-7.5 cells transfected with full-length HCV-GFP 
mRNA. Middle panel: inhibition of HCV positive- and negative-strand RNA levels in Huh-7.5 cells expressing NS3 antibody. Lower panel: shows HCV 
positive- and negative-strand HCV RNA levels in Huh-7.5 cells expressing control antibody.Chandra et al. Virology Journal 2010, 7:118
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Co-localization of intracellular antibody expression with 
HCV in replicon cells
To demonstrate intracellular antibody expression deliv-
ered by adenovirus, Huh-7.5 cells were infected with dif-
ferent doses of Ad-IgG1 and intracellular antibody
expression was determined by immunocytochemistry. A
very distinct bright immunostaining pattern was
observed suggesting high levels expression of antibody in
the entire cytoplasm but not in the nucleus (Fig. 8A).
None of the control cells showed staining suggesting that
high level and dose dependent expression of antibody can
be achieved using Ad-IgG1. Adenovirus mediated deliv-
ery of the antibody appears to be efficient since most of
the cells in the culture showed a dose dependent expres-
sion of the intracellular antibody. To determine if intrac-
ellular antibody molecules expressed are processed
accurately, Western blot analysis was performed using
the Ad-IgG1 infected Huh-7.5 cell lysates with goat-anti-
b o d i e s  t h a t  s p e c i f i c a l l y  b i n d  t o  t h e  F a b  p o r t i o n  o f  a
human IgG1 molecule (Fig. 8B). Two bands that corre-
spond to the molecular weight of heavy and light chain of
antibody molecule were detected in the extracts of Ad-
IgG1 infected Huh-7.5 cells but not in the mock infected
cells. These results suggested that antibody molecules are
Figure 4 Expression of GFP fusion protein in the Huh-7.5 cells expressing intracellular NS3 antibody and control antibody. Huh-7.5 cells were 
transfected with in vitro transcribed full-length HCV-GFP RNA. Cells were examined for GFP expression after 0, 24, 48, 72 and 96 hours of post transfec-
tion. Upper panel: shows HCV-GFP expression in Huh-7.5 cells transfected with full-length HCV-GFP mRNA. Middle panel: shows HCV-GFP expres-
sion was terminated after 96 hours in Huh-7.5 cells expressing NS3 antibody. Lower panel: shows no reduction in the level of HCV-GFP expression in 
Huh-7.5 cells expressing control antibody.
Figure 5 HCV RNA levels in Huh-7.5 cell lines after full-length 
HCV-GFP RNA transfection determined by real-time RT-PCR. Sta-
ble Huh-7.5 cells were transfected with in vitro transcribed full-length 
HCV-GFP RNA. Cells were harvested after 0, 24, 48, 72 and 96 hours of 
post transfection. Total RNA was isolated and subjected real-time PCR. 
(black diamond) Huh-7.5 only, (black triangle) Huh-7.5 cells expressing 
NS3 antibody, (black circle) Huh-7.5 cells expressing control antibody.Chandra et al. Virology Journal 2010, 7:118
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accurately processed and expressed high levels in the
cytoplasm of a liver derived cell line. In order to deter-
mine the extent of inhibition of HCV replication that
occurred due to intracellular expression of the antibody
in the cytoplasm of individual replicon cells, we per-
formed co-localization experiments using a GFP-tagged
replicon cell line. This cell line supports high levels of
replication of HCV JFH1-sub genomic RNA that can be
directly visualized by GFP expression. This S-3/GFP repl-
icon cell was infected with Ad-IgG1 virus. After 72 hours,
the antiviral efficacy of intracellular antibody expressed
from recombinant adenovirus vector was examined by
flow cytometric analysis (Fig. 9A). The S-3/GFP replicon
cells expressed high level of GFP that can be detected by
flow analysis. The expression of GFP was not altered
when infected with Adv-Luciferase. The GFP expression
was inhibited in S-3/GFP replicon cells infected with
Adenovirus carrying NS3 antibody gene. W e then per -
formed a co-localization experiment using the S-3/GFP
cells where intracellular antibody expression was exam-
ined using a phycoerythrin-labeled goat-anti-human
IgG1 antibody and HCV was detected by GFP expression.
Slides were randomly examined for antibody expression
as well as GFP expression under a fluorescence micro-
scope and fluorescence pictures in the same areas were
composed. We anticipate that if the antibody expression
inhibits HCV replication then one would expect not to
see GFP expression in the same replicon cells that express
intracellular antibody (Fig. 9B-F), suggesting that cells
expressing NS3 antibody showed negative expression for
GFP. Likewise cells showing GFP expression did not show
antibody expression. We did not observe hepatocytes
showing positive expression of both HCV (GFP) as well
as intracellular antibody (red) in the entire culture. These
results suggest that intracellular antibody expression in
individual replicon cells resulted in the inhibition of GFP
expression.
Figure 6 Infectivity assay of HCV-GFP chimera virus in Huh-7.5 cells expressing NS3 antibody and control antibody. Huh-7.5 cells (1 × 104) 
were seeded on a 2-well glass chamber slide, next day infected with JFH1-GFP virus for overnight at 37°C. Infected cells were examined for GFP ex-
pression after 24, 48, 72 and 96 hours of post infection. Superimposing blue (nucleus) with green fluorescence (HCV GFP) using the Abode Photoshop 
computer software generated the final image. Upper panel: shows HCV-GFP expression in Huh-7.5 cells infected with JFH1 virus. Middle panel: 
shows HCV-GFP expression was terminated in Huh-7.5 cells expressing NS3 antibody. Lower panel: shows no reduction in the level of HCV-GFP ex-
pression in Huh-7.5 cells expressing control antibody.Chandra et al. Virology Journal 2010, 7:118
http://www.virologyj.com/content/7/1/118
Page 9 of 12
Discussion
We described here a novel intracellular treatment
approach for chronic HCV infection using a humanized
recombinant antibody targeting the viral NS3 helicase
enzyme. We hypothesized that intracellular expression of
the antibody targeting the viral NS3 helicase should
inhibit its enzyme activity and HCV replication. The NS3
helicase enzyme is crucial for the HCV genome replica-
tion justifying it as potential target for ant-viral therapy
[41-43]. As a proof-of-principle, we have already shown
Figure 7 The production of infectious HCV particles in the Huh-
7.5 cells expressing NS3 antibody and control antibody. 1 × 106 
cells were seeded in a 100-mm plate was infected with HCV-GFP virus 
at a MOI of 1.5. Cell free supernatants were collected every 96 hours. 
Three milliliter of culture supernatants was used to infect freshly cul-
tured Huh-7.5 cells. The infectivity assay was repeated for four passag-
es. The production of infectious HCV using RNA extracts from 1 ml of 
culture supernatants was determined by real-time RT-PCR. (black dia-
mond) Huh-7.5 only, (black triangle) Huh-7.5 cells expressing NS3 anti-
body, (black square) Huh-7.5 cells expressing control antibody.
Figure 8 Intracytoplasmic expression of IgG1 antibody delivered 
by adenovirus vector. Left panel shows dose-dependent intracyto-
plasmic expression of IgG1 antibody in Huh7.5 cells delivered by ade-
novirus vector. Huh-7.5 cells were infected with increasing 
concentrations of Ad-IgG. After 24 hours, intracellular antibody expres-
sion was examined by immunostaining with a biotin conjugated goat 
anti-human IgG1 antibody. Slides were then counterstained with he-
matoxylin. 1: Mock infected cells showing negative staining. 2-4: Dose 
dependent intracytoplasmic brown staining was seen in majority of 
Huh-7.5 cells infected with Ad-IgG virus (A). Western blot analysis 
showing the presence of light chain and heavy chain antibody in the 
lysates of Huh-7.5 cells infected with Ad-IgG (B). Huh-7.5 cells were in-
fected with three different batches of recombinant Ad-IgG at a con-
centration of 4000 MOI. Cell lysates were made after 24 hours. 50 μg of 
protein lysates were separated on a 10% SDS PAGE and transferred to 
a nylon membrane. Immunoblotting was performed with peroxidase 
conjugated rabbit anti-human antibody. The membrane was devel-
oped using the ECL kit and was exposed to chemiluminescent-sensi-
tive film. 1. Uninfected Huh-7.5 cells. 2. Huh-7.5 cells infected with an 
adenovirus luciferase (Ad-Luc). 3-5. Huh-7.5 cells infected with three 
different batches of plaque-purified virus (Ad-IgG). Two specific bands 
at molecular weight 27 kD and 52 kD represent the light chain and the 
heavy chain of the IgG1 antibody respectively.
Figure 9 Intracellular antibody expression by adenovirus vector 
inhibits HCV replication in a sub-genomic GFP based stable repl-
icon cell line. Upper Panel shows flow cytometric analysis of HCV-
GFP protein level in replicon cell line expressing intracellular NS3 anti-
body from adenovirus vector. 1 × 106 replicon cells were seeded in a 
100 mm tissue culture dishes and next day they were infected with re-
combinant adenovirus (Ad-IgG or Ad-Luc). After 72 hours, cells were 
harvested by using trypsin-EDTA and then analyzed by a flow cytome-
ter where GFP expressing cells were quantified. Lower panel shows 
that intracellular antibody expression eliminates HCV GFP expression 
in replicon cell line in a co localization experiment. Replicon cells (2 × 
104) were grown in a 2-well chamber slide and after 24 hours cells were 
infected with increasing concentration of Ad-IgG (ranged from 50, 500, 
1000, 2000 and 4000 MOI). After 72 hours, cells were fixed for 15 min 
with 2% paraformaldehyde. This fixation did not destroy GFP expres-
sion. Intracellular expression of antibody was performed using phyco-
erythrin conjugated anti-human IgG1 antibody (1:50 dilution). After 
this step, cells were washed and counterstained with hoechst dye. 
Multiple areas in the slide were randomly examined. Three sets of pic-
tures from the same area were taken. First, the intracellular antibody 
expression (red), second for the GFP expression and third blue nuclear 
staining of stained cells under a fluorescent microscope. Finally, the 
combined picture in the same area was composed using Abode Pho-
toshop (version 7.0) computer software. A: Shows fairly high-level ex-
pression of HCV GFP the expression in S-3/GFP replicon cells. B-F: Co-
localization of GFP and intracellular antibody. The expression of GFP 
was decreased in cells infected with Ad-IgG and panel (B-E) the co-lo-
calization HCV-GFP (green) and intracellular antibody (red).Chandra et al. Virology Journal 2010, 7:118
http://www.virologyj.com/content/7/1/118
Page 10 of 12
that transient transfection of this human antibody clone
using a plasmid vector into HCV 1b replicon cell lines
inhibit HCV helicase activity and HCV RNA replication
[30]. The replicon-based model lacks the structural pro-
teins and does not produce infectious virus. Therefore we
performed this study to determine the success of inhibit-
ing full-length virus genome replication using this anti-
body clone.
The antiviral property of this antibody clone was exam-
ined using the highly efficient JFH1 clone belonging to
HCV 2a virus strain. This clone has now been widely
used by a number of investigatons to study the replication
of full-length virus genome after natural infection using
Huh-7.5 cell culture. For this reason, stable Huh-7.5 cell
lines were prepared that express HCV NS3 specific anti-
body and influenza specific control antibody. Huh-7.5
cells expressing intracellular antibody were cultured
using a medium containing G-418 selection. We showed
that Huh-7.5 cell expresses a recombinant antibody by
immunocytochemical staining. To study the effect of
antibody expression on HCV RNA replication, the HCV-
GFP chimeric clone was transfected to Huh-7.5 cells sta-
bly expressing either NS3 helicase antibody or a control
recombinant antibody. It was shown that HCV positive-
strand RNA, negative-strand RNA levels and NS5A-GFP
fusion protein expression was inhibited in Huh-7.5 cells
expressing intracellular antibody. The inhibition of viral
HCV RNA replication and protein expression was not
seen in control Huh-7.5 cells. The level of viral RNA rep-
lication was not altered in two other control cell lines,
including those expressing an antibody to influenza virus,
suggesting that this effect is specific to NS3 helicase anti-
body expression.
The inhibition of infectious virus particle production in
stable antibody expressing Huh-7.5 cell line was exam-
ined using an infectious cell culture system for over four
cycles of infectivity assay. We showed that the production
of HCV in the NS3 antibody expressed Huh-7.5 cells was
strongly inhibited and the titer of HCV remained below
the detection limit after first passage. The infectious
HCV particle production in two control Huh-7.5 cells
were maintained at a relatively high levels in the range of
107-105 copies of HCV RNA/ml in the culture superna-
tants. The results of multicycle infectivity assay support
the notion that intracellular NS3 antibody effectively sup-
pressed the virus replication and infectious virus produc-
tion. The intracellular antibody expression appears to
have effectively suppressed the production of infectious
HCV . In this study no evidence of escape mutant HCV
was observed over four passages. We showed that most of
the cells expressed antibody intracellular and inhibited
HCV expression by co-localization studies. We showed
that the antibody gene is accurately processed and
expressed at high levels using an adenovirus vector.
Recombinant antibody-based antiviral strategies for
HCV have been reported by a number of investigators.
Some of the recombinant antibodies are directed against
structural proteins [17,18,22,23,26-28,32]. Antibodies
targeted against E1 and E2 regions can be utilized to neu-
tralize HCV infection to cells in vitro as well as in vivo.
Likewise, it is expected that intracellular expression of
antibodies targeting the viral core protein should inter-
fere with formation of infectious virus production and
packaging. Some investigators have also developed
recombinant antibodies targeting the viral non-structural
proteins (NS3 protease, helicase and polymerase) of HCV
[20,24,25,29-31]. These antibodies should be used to
effectively block the viral protease, helicase and poly-
merase activity and thereby inhibit intracellular HCV
replication and infection. One of the major problems in
this antiviral strategy is the intracellular delivery of the
antibody for therapeutic approaches in human. As a
proof of principle we have demonstrated that intracellu-
lar inhibition of replication of the highly efficient JFH-1
virus clone can be achieved using an antibody clone tar-
geted to the NS3 helicase. We also showed that the intra-
cellular expression of a recombinant antibody to a liver
derived cell line efficiently inhibits JFH-1 virus replica-
tion and production. The replication-defective adenovi-
rus expresses high levels of therapeutic antibody in
cultured cells. This will allow large-scale antibody purifi-
cation from mammalian cells in culture. We realize that
the use of adenovirus has considerable adverse side
effects in humans; therefore, future research will focus on
developing safer non-viral delivery methods of targeted
delivery antibody to liver cells to inhibit HCV replication.
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